Health and Healthcare

Targacept Gets Mixed Results on Drug Trials (TRGT, AZN)

Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said it would not seek US Food and Drug Administration approval for its TC-5214 anti-depressant drug following a failed trial. AstraZeneca plc (NYSE: AZN) was Targacept’s partner on the development of TC-5214.

This morning the company announced that another development-stage drug, TC-6987, had failed an exploratory Phase 2 trial and that the company would no longer pursue approval for the drug as a treatment for diabetes. However the drug did meet its trial’s goals as an asthma drug, and Targacept’s CEO noted:

With the positive outcome in our TC-6987 asthma study, we have accomplished our goal of detecting in patients a signal of the potential of NNR [neuronal nicotinic receptors] Therapeutics in the treatment of disorders outside of the CNS, while at the same time further establishing a favorable safety and tolerability profile for this alpha7-selective NNR Therapeutic.

Targacept’s shares are down about -2.4% in early trading today, at $5.26 in a 52-week range of $4.90-$27.22.

Is Your Money Earning the Best Possible Rate? (Sponsor)

Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.

However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.

There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.